Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat

Neuroscience

Volumn 72, Issue 3, 1996, Pages 641-653

  Lee, C S ^a,b   Sauer, H ^a,c   Bjorklund A ^a  

^a LUND UNIVERSITY   (Sweden)

^b VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

^c GENENTECH INC   (United States)

Author keywords

6 hydroxydopamine; degeneration; Parkinson's disease; paw reaching; striatum; substantia nigra

Indexed keywords

OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINERGIC SYSTEM; FEMALE; IMMUNOCYTOCHEMISTRY; LOCOMOTION; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

EID: 0029981267     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/0306-4522(95)00571-4     Document Type: Article

References (39)

1. Agid Y., Javoy F. and Glowinski J. (1973) Hyperactivity of remaining dopaminergic neurones after partial destruction of the nigro-striatal dopaminergic system in the rat. Nature 245, 150-151.
2. Altar C. A., Marien M. R. and Marshall J. F. (1987) Time course of adaptations in dopamine biosynthesis, metabolism, and release following nigrostriatal lesions: implications for behavioral recovery from brain injury. J. Neurochem. 48, 390-399.
3. Berger K., Przedborski S. and Cadet J. L. (1991) Retrograde degeneration of nigrostriatal neurons induced by intrastriatal injection in rats. Brain Res. Bull. 26, 301-307.
4. Björklund A. and Lindvall O. (1984) Dopamine-containing systems in the CNS. In Handbook of Chemical Neuroanatomy. Vol. 2: Classical Transmitters in the CNS (eds Björklund A., Hökfelt T. and Kuhar M. J.), pp. 55-122. Elsevier, Amsterdam.
5. Burns R. S., Chiueh C. C., Markey S. P., Ebert M. H., Jacobowitz D. M. and Kopin I. J. (1983) A primate model of Parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. natn. Acad. Sci. U.S.A. 890, 4546-4550.
6. Cadet J. L., Last R., Kostic V., Przedborski S. and Jackson-Lewis V. (1991) Long-term behavioral and biochemical effects of 6-hydroxydopamine injections in rat caudate-putamen. Brain Res. Bull. 26, 707-713.
7. Creese I., Burt D. R. and Snyder S. H. (1977) Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity. Science 197, 596-598.
8. 3H spiroperidol binding. Eur. J. Pharmac. 56, 277-281.
9. Dahlström A. and Fuxe K. (1964) Evidence for the existence of monoamine neurons in the central nervous system I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta physiol. scand. Suppl. 232, 1-55.
10. Fahn S. and Cohen G. (1992) The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann. Neurol. 31, 804-812.
11. Fearnley J. M. and Lees A. J. (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114, 2283-2301.
12. Hefti F., Melamed E. and Wurtman R. J. (1980) Partial lesions of the dopaminergic nigrostriatal pathway in rat brain: biochemical characterization. Brain Res. 195, 123-137.
13. Ichitani Y., Okamura H., Matsumoto Y., Nagatsu I. and Ibata Y. (1991) Degeneration of the nigral dopamine neurons after 6-hydroxydopamine injection into the rat striatum. Brain Res. 549, 350-353.
14. Ichitani Y., Okamura H., Nakahara D., Nagatsu I. and Ibata Y. (1994) Biochemical and immunocytochemical changes induced by intrastriatal 6-hydroxydopamine injection in the rat nigrostriatal dopamine neuron system: evidence for cell death in the substantia nigra. Expl. Neurol. 130, 269-278.
15. Jackson E. A. and Kelly P. H. (1983) Nigral dopaminergic mechanisms in drug-induced circling. Brain Res. Bull. 11, 605-611.
16. Kish S. J., Shannak K., Rajput A., Deck J. H. N. and Hornykiewicz O. (1992) Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease. J. Neurochem. 58, 642-648.
17. LaHoste G. J. and Marshall J. F. (1990) Nigral D1 and striatal D2 receptors mediate the behavioral effects of dopamine agonists. Behav. Brain Res. 38, 233-242.
18. Lee C. S., Schulzer M., Mak E., Snow B. J., Tsui J. K., Calne S., Hammerstad J. and Calne D. B. (1994) Clinical observations on the rate of progression of idiopathic Parkinsonism and a mathematical model of pathogenesis: part I. Clinical observations. Brain 117, 501-507.
19. Mann D. M. and Yates P. O. (1983) Possible role of neuromelanin in the pathogenesis of Parkinson's disease. Mech. Agng Devl. 21, 193-203.
20. Montoya C. P., Campbell H. L., Pemberton K. D. and Dunnett S. B. (1991) The 'staircase test': a measure of independent forelimb reaching and grasping abilities in rats. J. Neurosci. Meth. 36, 2-3.
21. Nikkhah G., Bentlage C., Cunningham M. G. and Björklund A. (1994) Intranigral fetal dopamine grafts induce behavioral compensation in the rat Parkinson model. J. Neurosci. 14, 3449-3461.
22. Olanow C. M. (1993) A radical hypothesis for neurodegeneration. Trends Neurosci. 16, 439-444.
23. Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 328, 176-183.
24. Pasinetti G. M., Osterburg H. H., Kelly A. B., Kohama S., Morgan D. G., Reinhard J. F., Stellwagen R. H. and Finch C. E. (1992) Slow changes of tyrosine hydroxylase gene expression in dopaminergic brain neurons after neurotoxin lesioning: a model for neuron aging. Molec. Brain Res. 13, 63-73.
25. Paxinos G. and Watson C. (1986) The Rat Brain in Stereotaxic Coordinates, 2nd ed. Academic Press, San Diego.
26. Przedborski S., Levivier M., Jiang H., Ferreira M., Jackson-Lewis V., Donaldson D. and Togasaki D. M. (1995) Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 67, 631-647.
27. Riederer P. and Wuketich S. (1976) Time course of nigrostriatal degeneration in Parkinson's disease. J. neural Transm. 38, 277-301.
28. Rioux L., Gaudin D. P., Gagnon C., DiPaolo T. and Bédard P. J. (1991) Decrease of behavioral and biochemical denervation supersensitivity of rat striatum by nigral transplants. Neuroscience 44, 75-83.
29. Robertson H. A. (1992) Dopamine receptor interactions: some implications for the treatment of Parkinson's disease. Trends Neurosci. 15, 201-206.
30. Robinson T. E. and Whishaw I. Q. (1988) Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: a microdialysis study in freely moving rats. Brain Res. 450, 209-224.
31. Sauer H., Rosenblad C. and Björklund A. (1995) Glial cell line-derived neurotrophic factor but not transforming growth factor β3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc. natl Acad. Sci. U.S.A. 92, 8935-8939.
32. Sauer H. and Oertel W. H. (1994) Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-OHDA: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59, 401-415.
33. 14C] 2-deoxy-D-glucose autoradiography. J. Neurochem. 38, 737-774.
34. Sundström E., Fredriksson A. and Archer T. (1990) Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson's disease. Brain Res. 528, 181-188.
35. Ungerstedt U. (1968) 6-Hydroxydopamine induced degeneration of central monoamine neurons. Eur. J. Pharmac. 5, 107-110.
36. Ungerstedt U. and Arbuthnott G. W. (1970) Quantitative recording of rotational behavior in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res. 24, 485-493.
37. Youdim M. B., Lavie L. and Riederer P. (1994) Oxygen free radicals and neurodegeneration in Parkinson's disease: a role for nitric oxide. Ann. N.Y. Acad. Sci. 738, 64-68.
38. Zetterström T., Sharp T., Collin A. K. and Ungerstedt U. (1988) In vivo measurement of extracellular dopamine and DOPAC in rat striatum after various dopamine-releasing drugs; implications for the origin of extracellular DOPAC. Eur. J. Pharmac. 148, 327-334.
39. Zigmond M. J., Abercrombie E. D., Berger T. W., Grace A. A. and Stricker E. M. (1990) Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 13, 290-296.